Genetic susceptibility to breast and ovarian cancer assessment, counseling, and testing guidelines

The Guidelines have been prepared to help the primary care provider to participate in the pre- and post-test education and counseling required for every patient contemplating genetic testing for breast and ovarian cancer. Although some important genetic, epidemiological, and clinical issues remain u...

Full description

Bibliographic Details
Corporate Author: American College of Medical Genetics
Format: eBook
Language:English
Published: Bethesda (MD) American College of Medical Genetics 1999, 1999
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01882nam a2200289 u 4500
001 EB002002371
003 EBX01000000000000001165272
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a Genetic susceptibility to breast and ovarian cancer  |h Elektronische Ressource  |b assessment, counseling, and testing guidelines 
260 |a Bethesda (MD)  |b American College of Medical Genetics  |c 1999, 1999 
300 |a 1 online resource 
505 0 |a Includes bibliographical references 
653 |a Genetic Predisposition to Disease 
653 |a Primary Health Care / methods 
653 |a Genetic Testing 
653 |a Ovarian Neoplasms / genetics 
653 |a Breast Neoplasms / genetics 
653 |a Genetic Counseling 
710 2 |a American College of Medical Genetics 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
500 |a Title form HTML header 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK56955  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The Guidelines have been prepared to help the primary care provider to participate in the pre- and post-test education and counseling required for every patient contemplating genetic testing for breast and ovarian cancer. Although some important genetic, epidemiological, and clinical issues remain unresolved, it is essential that all health care providers understand the familial basis of some cancers and the potential applications of genetic testing as part of the risk assessment process. The Guidelines do not comment on who should provide the counseling, nor try to demarcate where risk assessment leaves off and genetic counseling begins. It is hoped that the enhanced collaborative relationships encouraged in the Guidelines will improve quality of care provided to all patients